For anyone who has been following the oncology field in the last few years, the term radioligand therapy has been showing up more often. It has become one of the busiest corners of cancer drug development, with billions in capital moving in and a wave of late-stage data on the horizon. Curasight offers a useful test case for anyone trying to make sense of the field – not because it is the biggest name, but because it sits at the intersection of most of the trends now shaping it. BioStock takes a closer look.
Read the full interview at biostock.se:
Curasight nears topline results in brain and prostate cancer
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/